Repligen Corp. (RGEN) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. Repligen Corporation is a global life sciences company developing bioprocessing technologies for the manufacturing of biological drugs. The company operates as a single reportable segment. As of July 24, 2026, there were 56,435,621 shares of common stock outstanding.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Amount (in thousands) |
|---|---|
| Total Revenue | $398,383 |
| Net Income | $13,341 |
| Diluted EPS | $0.24 |
| Operating Cash Flow | $61,061 |
| Cash and Cash Equivalents | $606,783 |
| Marketable Securities | $203,666 |
| Total Liquidity | $810,449 |
| Convertible Senior Notes (Carrying Value) | $551,046 |
| Gross Margin | 54.8% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 13.3% year-over-year (YoY) to $398.4 million, driven by a 13.3% increase in product revenue. Growth was broad-based, with significant increases in Asia Pacific (36.1%) and North America (11.2%).
- Profitability: Net income decreased 35.5% YoY to $13.3 million. This decline was primarily due to a $13.7 million loss on the sale of Polymem S.A.S. and a higher effective tax rate for the quarter (64.6%) compared to the prior year.
- Operating Expenses: Total costs and operating expenses rose 11.3% YoY. SG&A increased 8.2% due to headcount investments, and R&D increased 10.7% largely due to the integration of the 908 Devices PAT Portfolio.
- Restructuring: The company initiated new restructuring activities in Q1 2026 to optimize its global manufacturing footprint, resulting in $4.2 million in charges for the six-month period.
- Divestiture: Completed the sale of Polymem S.A.S. in March 2026 for $3.6 million net consideration, recognizing a significant loss on the transaction.
Guidance, Outlook, and Risks
- Strategic Acquisition: On July 21, 2026, Repligen entered into an agreement to acquire BioLife Solutions, Inc. for approximately $1.5 billion (64% stock, 36% cash). Closing is expected in Q4 2026. The cash portion will be funded from existing cash and equivalents.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of June 30, 2026, due to previously reported material weaknesses in IT general controls and business process-level controls related to inventory valuation. Remediation efforts are ongoing.
- Tax Legislation: The company noted the enactment of the "One Big Beautiful Bill Act" (OBBBA) in July 2025, though it does not expect a material impact on future financial statements.
- Macro Risks: Management highlighted risks related to global geopolitical conflicts, supply chain challenges, foreign currency fluctuations, and potential changes in U.S. trade policy/tariffs.
Investor Verification Checklist
- BioLife Acquisition Status: Verify the progress of closing conditions for the $1.5 billion BioLife acquisition and the impact on future dilution and cash reserves.
- Internal Control Remediation: Monitor the timeline and effectiveness of remediation plans for the material weaknesses in IT and inventory valuation controls.
- Restructuring Progress: Track the execution of the 2026 restructuring plan and the realization of expected cost synergies by the end of 2027.
- Polymem Loss Impact: Assess whether the $13.7 million loss on the Polymem divestiture was a one-time event or indicative of broader asset valuation issues.
- Convertible Notes: Review the conversion triggers for the $600 million 2028 Convertible Senior Notes, noting they were not triggered in Q2 2026.